Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting by Albrecht, Philipp et al.
 
 
 
 
 
Dieses Dokument ist eine Zweitveröffentlichung (Verlagsversion) / 
This is a self-archiving document (published version):  
 
 
 
 
 
 
 
 
 
 
Diese Version ist verfügbar / This version is available on:  
https://nbn-resolving.org/urn:nbn:de:bsz:14-qucosa2-355442 
 
 
 
„Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFGgeförderten) Allianz- bzw. 
Nationallizenz frei zugänglich.“ 
 
This publication is openly accessible with the permission of the copyright owner. The permission is 
granted within a nationwide license, supported by the German Research Foundation (abbr. in German 
DFG). 
www.nationallizenzen.de/ 
 
 
 
Philipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, Rachel Farrell, Peter Feys, Jeremy 
Hobart, Raymond Hupperts, Michael Linnebank, Jožef Magdič, Celia Oreja-Guevara, Carlo 
Pozzilli, Antonio Vasco Salgado, Tjalf Ziemssen 
Prolonged-release fampridine in multiple sclerosis: clinical data and 
real-world experience. Report of an expert meeting 
 
Erstveröffentlichung in / First published in: 
Therapeutic Advances in Neurological Disorders. 2018, 11, S. 1 – 8 [Zugriff am: 08.08.2019]. 
SAGE journals. ISSN 1756-2864. 
DOI: https://doi.org/10.1177/1756286418803248 
 
 
https://doi.org/10.1177/1756286418803248 
https://doi.org/10.1177/1756286418803248
Therapeutic Advances in Neurological Disorders
journals.sagepub.com/home/tan 1
Ther Adv Neurol Disord
2018, Vol. 11: 1–8
DOI: 10.1177/ 
1756286418803248
© The Author(s), 2018.  
Article reuse guidelines:  
sagepub.com/journals-
permissions
Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License  
(http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission 
provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Introduction
Multiple sclerosis (MS) causes a wide variety of 
neurological deficits, but ambulatory impairment is 
the most common form of disability. Within 
15 years of disease onset, 50% of people with MS 
will require assistance with walking and 80% will 
experience gait problems due to muscle weakness, 
spasticity, fatigue and balance impairment.1 In a 
large United States (US) cohort, 15% of MS 
patients reported needing ambulatory aid in the first 
year of disease, increasing to 40% after 10 years; 
after 45 years of disease, 76% of patients required 
ambulatory aid and 52% needed at least bilateral 
assistance.2 Impaired mobility is associated with 
reductions in quality of life, activities of daily living 
and productivity, and patients with MS rank main-
taining mobility as one of their highest priorities.3,4
Prolonged-release (PR) fampridine (known as 
sustained/modified-release fampridine in some 
countries and extended-release dalfampridine in 
the US) is the only approved medication for MS 
that improves walking. It received full approval 
from the European Medicines Agency (EMA) in 
May 2017, following approval in 2011 condi-
tional on further studies being conducted. 
PR-fampridine is indicated for the improvement 
of walking in adult MS patients with walking dis-
ability [Expanded Disability Status Scale (EDSS) 
score 4–7].5 Fampridine is thought to block volt-
age-gated potassium channels, restoring signal 
conduction in demyelinated nerve fibres.6
This article describes new responder subgroup 
analyses of the ENHANCE study, which clarify 
treatment effects in patients who respond to 
PR-fampridine. It also reports on the clinical 
experience of 14 MS experts from 10 European 
countries (Belgium, France, Germany, Italy, 
Netherlands, Norway, Portugal, Slovenia, Spain 
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and the United Kingdom), which was discussed 
at a meeting held in June 2017. Topics discussed 
include real-world experience with PR-fampridine, 
expert views on the patient population for 
PR-fampridine, assessment of treatment response, 
re-testing and re-treatment, and stopping criteria, 
based on early European Union (EU) clinical 
experience.
New analyses of the fampridine study 
program: understanding the real patient 
impact
Two phase III multicentre, randomized, double-
blind, placebo-controlled trials showed that 
PR-fampridine produced clinically meaningful 
improvement in walking ability in a subset of MS 
patients.7,8 In the first trial, the proportion of 
patients with any type of MS who responded 
[consistent improvement on Timed 25-Foot 
Walk (T25FW) over 14 weeks] was significantly 
higher in the PR-fampridine group than in the 
placebo group (35% versus 8%; p < 0.0001). 
T25FW responders showed greater improvement 
on the 12-item Multiple Sclerosis Walking Scale 
(MSWS-12) than did nonresponders (p = 
0.0002).7 The T25FW is considered the most 
well-characterized objective, specific assessment 
of walking disability, and is moderately to strongly 
correlated with self-reported walking disability on 
the MSWS-12.9 The second trial confirmed these 
findings, with 43% of the PR-fampridine group 
being T25FW responders compared with 9% of 
the placebo group (p < 0.0001).8 Long-term 
extensions of the two trials showed that improve-
ments in walking speed were lost after 
PR-fampridine was discontinued in the parent 
trial, but returned by the 2-week assessment after 
re-initiation. Although walking speed decreased 
over time, PR-fampridine responders sustained 
an improved walking speed compared with non-
responders for up to 5 years.10
The MOBILE trial explored the effect of 
PR-fampridine on patients’ self-assessed walking 
ability and dynamic/static balance, assessed using 
the MSWS-12, the Timed Up and Go (TUG) 
test and the Berg Balance Scale (BBS).11 
PR-fampridine therapy resulted in greater median 
improvements from baseline in MSWS-12 score, 
TUG speed and BBS total score versus placebo 
over 24 weeks, as well as greater improvements in 
the 29-item MS Impact Scale (MSIS-29) physi-
cal impact subscale (PHYS).11 A post-hoc analysis 
showed a mean reduction from baseline of 97% 
versus placebo in MSIS-29 PHYS among patients 
who achieved a clinically significant ⩾8-point 
mean reduction in MSWS-12 score over 24 weeks 
with PR-fampridine, and a reduction of 111% in 
the psychological subscale of MSIS-29.12
ENHANCE, the largest and longest randomized 
trial of PR-fampridine to date, was a phase III 
multicentre, randomized, double-blind, placebo-
controlled study to evaluate whether 
PR-fampridine provided sustained, clinically 
meaningful benefits compared with placebo on 
patient-reported walking ability and other func-
tional outcome measures.13 Patients aged 18–
70 years with relapsing or progressive MS and 
impaired walking (EDSS 4–7) were randomized 
to PR-fampridine 10 mg (n = 317) or placebo (n 
= 319) twice daily for 24 weeks. Significantly 
more patients in the PR-fampridine group than in 
the placebo group achieved a clinically meaning-
ful ⩾8-point mean improvement from baseline 
on the MSWS-12 over 24 weeks. Significant dif-
ferences in favour of PR-fampridine were also 
reported for TUG speed and improvement from 
baseline MSIS-29 PHYS.13 Overall tolerability of 
PR-fampridine in the ENHANCE trial was con-
sistent with previous clinical trials.
Recent responder subgroup analyses in 
ENHANCE showed an improvement in MSWS-
12 score of 20.58 points among PR-fampridine 
MSWS-12 responders, compared with a deteriora-
tion of 2.17 points [least square mean (LSM) dif-
ference −22.76; 95% confidence interval (CI) 
−25.25 to −20.26] in nonresponders and an 
improvement of 3.64 (LSM difference −16.94; 
95% CI −19.21 to −14.68) in placebo-treated 
patients.14 The proportion of patients with clini-
cally significant improvements (⩾15%) in TUG 
speed was significantly higher in PR-fampridine 
responders (52.4%; 95% CI, 1.47–3.53) than in 
nonresponders (36.6%) or the placebo group 
(34.7%). Improvements in MSWS-12 scores and 
TUG speeds in responders were observed as early 
as Week 2 and were sustained over 24 weeks. 
Benefits were also seen in responders versus nonre-
sponders/placebo for changes in MSIS-29 PHYS, 
BBS and ABILHAND scores over 24 weeks.14 
LSM changes from baseline were −17.4 in 
responders, −1.9 in nonresponders and −5.3 with 
placebo for MSIS-29 PHYS; 2.6, 1.2 and 1.4, 
respectively for BBS; and 3.3, 0.3 and 0.9, respec-
tively, for ABILHAND. The experts who met in 
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June 2017 considered that this responder subgroup 
analysis approach was justified because, in clinical 
practice, only patients who respond to 
PR-fampridine remain on treatment.
New effect size analyses have been conducted 
with the aim of contextualizing the effect sizes 
seen in the PR-fampridine responder and nonre-
sponder subgroups in ENHANCE. These exam-
ined the mean change in points on the MSWS-12 
scale relative to the standard deviation of change 
and have specific criteria for interpretation. 
Standardized response mean values were calcu-
lated for PR-fampridine MSWS-12 responder 
and nonresponder groups as 1.68 and 0.36, 
respectively, for MSWS-12. As many studies are 
powered to detect an effect size of 0.3, an effect 
size of 1.68 in responders was thought to repre-
sent an impressive result. Similar calculations 
were conducted for other outcome measures from 
ENHANCE, such as effect versus baseline disa-
bility and BBS at baseline, with PR-fampridine 
MSWS-12 responders showing strong results rel-
ative to nonresponders.
Real-word experience with PR-fampridine
PR-fampridine received full EMA approval in 
May 2017, following conditional approval in 
2011. However, worldwide experience is much 
more extensive and, as of 30 April 2017, more 
than 318,565 patients had been treated with 
PR-fampridine, representing more than 341,163 
patient-years of exposure (including ~8321 
patients and ~3367 patient-years from clinical tri-
als; data on file, Biogen, 13 July 2017).
Use of PR-fampridine in clinical practice varies 
across Europe, depending partly on whether it is 
reimbursed. Healthcare systems in many 
European countries now reimburse PR-fampridine 
subject to certain response criteria. However, 
reimbursement is not currently available in the 
UK and several other countries, meaning that 
access to PR-fampridine treatment for people 
with MS remains variable. PR-fampridine is less 
well documented in real-world multicentre activi-
ties or national MS registries than other products, 
although the first publications describing multi-
centre observational studies, rather than single-
centre cohorts, are beginning to appear.15–17
The experts who met in June 2017 have a broad 
experience of using PR-fampridine in their MS 
patients, which was assessed by questionnaires at 
the meeting: the group of experts oversees a total 
of over 11,000 patients, over 1400 of these under 
treatment with PR-fampridine. Due to different 
local situations regarding healthcare systems as 
well as license and reimbursement of the drug in 
the different countries the rate of fampridine 
treated patients differs between the experts’ cen-
tres, ranging from below 10% in Belgium and 
Italy to around 25% in Germany and Spain to 
about 40% in Denmark. The majority of the 
PR-fampridine treated patients at the centres 
were classified as secondary progressive MS 
(48%), followed by relapsing remitting (35%) 
and primary progressive (17%) MS with a rather 
homogenous distribution over the EDSS steps 4 
(21%), 5 (23%), 6 (35%) and 7 (21%). The 
experts often use PR-fampridine in combination 
with disease-modifying therapies, as well as with 
nonpharmacological approaches such as physio-
therapy and occupational therapy. Half of their 
currently treated patients have been taking 
PR-fampridine for 3–4 years, with another 30% 
taking it for 5 or more years.
Patient population: which patients are most 
likely to benefit from PR-fampridine?
PR-fampridine is currently indicated for the 
improvement of walking in adults with MS who 
have walking disability (EDSS 4–7). However, 
the experts believe that some people with MS 
even with EDSS scores below 4 may already have 
impaired walking18 and other deficits such as vis-
ual impairment, nystagmus or ataxia, and may 
receive considerable benefit from PR-fampridine 
treatment. This is supported by reports on an 
improvement of visual acuity and visual evoked 
potential latencies in patients with optic neuropa-
thy,19 an amelioration of downbeat nystagmus20,21 
and ataxia22 under therapy with 4-aminopyridine 
also in non-MS patients. How patients walk can 
be as important as how far or how fast they can 
walk. Similarly, at higher EDSS levels, meaning-
ful and impactful improvements in hand function 
may be achievable; these are less apparent as 
study populations do not include patients with 
major hand dysfunction. As PR-fampridine works 
by improving neuronal function, the experts sug-
gested that it may lead to greater improvement in 
patients with more deficits. Even very disabled 
patients may be able to use their wheelchairs 
more easily and effectively. Overall, more data on 
the use of PR-fampridine in patients with EDSS 
Therapeutic Advances in Neurological Disorders 11
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scores below 4 and above 7 would be welcome, 
including information on walking impairment, 
fatigue, upper limb function and cognition.
Newer tools that have a potential role in identify-
ing patients with mobility impairment who may 
benefit from PR-fampridine treatment were dis-
cussed. For example, the Early Mobility 
Impairment Questionnaire (EMIQ) is a nine-item 
questionnaire designed to capture MS patients’ 
experience with mobility impairment.23 It includes 
more high-level motor activities than the MSWS-
12, such as items on walking in crowds and stabil-
ity while walking on flat or uneven ground. Early 
experience suggests that it has the potential to be 
used as a screening tool to identify mobility 
impairment at an earlier stage.
With regards to a concordant relationship and 
shared decision making, clear communication is 
needed when prescribing PR-fampridine, so that 
patients have realistic expectations. It is impor-
tant to explain to patients that not everyone expe-
riences an improvement; however, they will know 
very quickly whether the drug works for them or 
not. The experience of the experts suggests that 
most patients are very positive about trying the 
drug.
Assessing treatment response
The EU label for PR-fampridine has recently 
been updated to recommend that clinical benefit 
is evaluated on the basis of walking ability rather 
than walking speed as specified previously, and 
the timescale for initial evaluation is now ‘within 
2–4 weeks’, rather than ‘after 2 weeks,’ which 
had been recommended previously. Both MSWS-
12 and T25FW are included in the label as suit-
able tools for evaluating response to allow both 
clinical and patient-reported assessments.
Variations exist across Europe in terms of the 
documented evidence of response required by the 
various authorities for reimbursement purposes, 
and in some cases this drives the methods used to 
evaluate response. At the meeting, the experts 
agreed that the patient-reported MSWS-12 is 
currently the most commonly used measure for 
formal assessment of treatment response, along 
with T25FW. Some would use extra measures, 
such as assessment of hand function using the 
9-Hole Peg Test or ABILHAND, if a patient has 
additional deficits. A recent single-centre study 
found that a combination of the T25FW and 
MSWS-12 offered the best sensitivity and speci-
ficity for determining response to both neurolo-
gists’ and patients’ classification.17 Thresholds for 
reimbursement need to be pragmatic; each 
authority sets its own threshold, with an improve-
ment of 30% on MSWS-12 or 20% on T25FW 
being commonly used. The experts noted that in 
many cases, it is obvious after 2 weeks whether a 
patient is responding to PR-fampridine; however, 
some patients may need to continue treatment for 
a further 2 weeks to be certain.
Based on the experts’ real-world experience with 
PR-fampridine, there was agreement that the 
benefits of PR-fampridine to patients may be 
broader than just on walking speed. Several 
experts stated that patients could see improve-
ments in terms of gait pattern, walking endur-
ance, balance and fatigability. The experts noted 
that patients have better balance when taking 
PR-fampridine; they may not walk faster but they 
feel safer.24–27 The Timed 100-Meter Walk Test 
may be useful for assessing walking speed over a 
longer distance,28 while a cutoff of 15% change 
from the first to the last minute of the 6-Minute 
Walk Test (6MWT) has been suggested to iden-
tify walking-related motor fatigue,29 which may 
be affected by PR-fampridine. Some experts also 
reported improvements in vision and ataxia, 
although these are not included in the label indi-
cation. As the mode of action of PR-fampridine is 
to improve nerve conduction, it was thought that 
treatment benefits were unlikely to be confined to 
walking ability alone. Indeed, PR-fampridine has 
been shown to improve arm function, fatigue and 
quality of life in T25FW/MSWS-12/2-minute 
walk test responders.30 The 9-Hole Peg Test is 
likely to be useful for monitoring hand function, 
as it is a simple, validated measure of upper limb 
function in MS and is highly correlated with a 
wide range of other upper limb tests.31 
Improvement has also been demonstrated with 
PR-fampridine treatment.32 In addition, 
PR-fampridine has been shown to significantly 
improve cognitive impairment in a single-centre 
study, as measured by processing speed according 
to the Symbol Digit Modalities Test.33
This expert group agreed that patient-reported 
outcomes were particularly important for a treat-
ment that improves symptoms, and that prede-
fined questionnaires and rating scales inevitably 
have their limitations in assessing overall clinical 
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improvements. Specific goal-related outcomes 
such as the ability to walk upstairs or reach the 
bathroom may be of real practical significance to 
people with MS and can be measured using goal 
attainment scaling.34 The ability to walk confi-
dently with one walking aid rather than two could 
also be a meaningful outcome in some cases.
Overall, as PR-fampridine is a symptomatic treat-
ment, the experts agreed that it would seem rea-
sonable to be able to continue treatment if both 
the physician and the patient believe that the drug 
is working, and that patients would generally be 
unwilling to take a drug that was not effective for 
them. This is evident in countries such as the UK, 
where PR-fampridine is not reimbursed and 
patients must decide whether to pay for the drug 
themselves.
Based on the label recommendation, treatment 
should be stopped if the patient reports no benefit 
from PR-fampridine after 2–4 weeks. However, 
the experts noted that some patients may deterio-
rate when the drug is stopped, suggesting that 
they were receiving some benefit from treatment. 
The effect of stopping PR-fampridine appears to 
distinguish quite well between responders and 
nonresponders. Furthermore, disease activity and 
clinical symptoms may progress, and the experts 
noted that in some cases response to fampridine 
may change later in the course of disease despite 
an earlier negative response (see below).
Re-testing, stopping treatment and re-
treating
On the basis of their practical experience, the 
experts considered that asking PR-fampridine-
treated patients every 6 months whether the drug 
is still working for them was good practice, as well 
as assessing them for side effects, walking ability 
and other outcomes. Drug holidays could be used 
to determine whether the drug still has a thera-
peutic benefit. If it no longer appears to be effec-
tive, the drug should be stopped. However, there 
is the possibility of re-starting treatment if the 
clinical situation changes. EDSS > 7 is generally 
used as a stopping criterion for PR-fampridine 
treatment in current clinical practice, based on 
the label, but different criteria may be needed for 
other domains such as hand function.
A recent long-term extension of a randomized 
controlled trial of PR-fampridine found that 80% 
of patients who showed greater than 10% 
improvement in T25FW and 6MWT in the origi-
nal study maintained their response over 2 years 
in the extension. However, 40% of patients who 
did not achieve this level of response during short-
term treatment (6 weeks) showed greater than 
10% improvements after 2 years.35 The authors 
speculate that responsiveness to PR-fampridine 
may change over time, as MS is a dynamic disease 
and appearance of new demyelinated lesions may 
result in clinical deterioration amenable to 
improvement; enhanced drug efficacy over time 
may also be the result of training effects made 
possible by the improved neurological state 
induced by PR-fampridine.35
In the experts’ experience, some people with MS 
(possibly as many as a third) who initially do not 
respond to fampridine may respond to a second 
attempt at treatment. A re-trial of PR-fampridine 
between 6 and 12 months after an initial failure is a 
reasonable approach, especially if the disease course 
has changed and if the person with MS is willing to 
try the treatment again. Some patients may not 
wish to try a drug again if it did not work for them 
on the first attempt, but an increase in symptoms or 
disability may prompt a second attempt.
Conclusion
PR-fampridine has been shown to improve walk-
ing ability in a subset of MS patients with impaired 
mobility, and recent responder subgroup analyses 
of the ENHANCE study have shown very large 
effect sizes in terms of an average increase in 
MSWS-12 score of 20.58 points among 
PR-fampridine MSWS-12 responders. Similarly, 
more than 52% of PR-fampridine MSWS-12 
responders showed meaningful improvements in 
TUG speed.
Early real-world experience suggests that the ben-
efits of PR-fampridine may extend beyond those 
on walking ability, based on its mode of action 
which involves restoring neuronal function.
This article has provided expert opinions on how 
PR-fampridine can be used in real-world clinical 
practice to optimize the benefits to people with 
MS with impaired walking ability.
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